Raltegravir was generally well tolerated when used in combination with optimized background therapy regimens in treatment-experienced patients with HIV-1 infection in trials of up to 48 weeks' duration.<ref name="ralegravir">{{cite journal|vauthors=Croxtall JD, Keam SJ |url=http://adisonline.com/drugs/abstract/2009/69080/Raltegravir__A_Review_of_its_Use_in_the_Management.7.aspx |journal=Drugs |year=2009 |volume=69|pmid=19496631 |issue=8 |doi= 10.2165/00003495-200969080-00007|title=Raltegravir|pages=1059â€“75}}</ref>

 

